ClinicalTrials.gg
RecruitingNCT07853482RCT-TAP-ESP-CSUpdated Nov 18, 2026

TAP vs. ESP Blocks for Post-Cesarean Analgesia

An interventional study of Ropivacaine and Ultrasound-guided Nerve Block in Postoperative Pain After Cesarean Section, sponsored by Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog. Recruiting at 1 site in Russia. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.

Planned enrollment
18th of 184
162 · median 70
Started
2026
with 4 others
No phase
61 of 184
8 open now
Primary completion
2027-05
later than 18 of 21 live
Registered
184th of 184
by date

Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 18th largest by planned enrollment, is one of 5 that started in 2026, is one of 61 with no phase, reaches primary completion later than 18 of the 21 other live ones, and was the 184th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies testing ropivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This study compares the effectiveness of two ultrasound-guided nerve blocks (TAP block and ESP block) versus standard pain management for relieving pain after a planned cesarean section.

Cesarean delivery often causes moderate to severe pain, which can be divided into somatic pain (from the abdominal incision) and visceral pain (from uterine contractions and internal tissues). While transversus abdominis plane (TAP) blocks are commonly used, erector spinae plane (ESP) blocks are a newer technique that may provide better relief for visceral pain.

In this randomized controlled trial, 162 women undergoing elective cesarean delivery under spinal anesthesia will be assigned to one of three groups:

  1. Bilateral ESP block at the L1 level;
  2. Bilateral TAP block;
  3. Standard analgesia without nerve blocks.

The primary goal is to determine which method provides better control of visceral pain in the first 16 hours after surgery. Secondary goals include assessing somatic pain, time to first mobilization, time to first skin-to-skin contact with the baby, and the need for additional rescue pain medication. The study aims to support early recovery and improve mother-infant bonding by optimizing postoperative pain control.

Read the detailed description

Background:

Postoperative pain after cesarean delivery has a dual nature: a somatic component resulting from the abdominal wall incision and a visceral component arising from uterine contraction and tissue trauma (innervated by Th10-L1 segments). According to PROSPECT (2021) guidelines, multimodal analgesia is the standard of care. Interfascial plane blocks, such as the Transversus Abdominis Plane (TAP) block and the Erector Spinae Plane (ESP) block, have shown efficacy in controlling somatic pain. However, data comparing their differential efficacy on visceral versus somatic pain components are limited. The ESP block, performed at the L1 level, theoretically offers superior visceral analgesia due to the spread of local anesthetic to the dorsal rami of spinal nerves and potential craniocaudal spread into the paravertebral/epidural space.

Study Design:

This is a prospective, single-center, randomized, single-blind controlled trial conducted at the Maternity Hospital in Taganrog, Rostov Oblast, Russia. A total of 162 patients undergoing elective cesarean delivery under spinal anesthesia will be enrolled. Participants will be randomly assigned in a 1:1:1 ratio to one of three parallel groups:

  1. ESP Block Group: Patients will receive a bilateral ultrasound-guided ESP block at the L1 level in the post-anesthesia care unit. 20 mL of 0.375% ropivacaine will be injected on each side (total 40 mL).
  2. TAP Block Group: Patients will receive a bilateral ultrasound-guided TAP block in the post-anesthesia care unit. 20 mL of 0.375% ropivacaine will be injected on each side (total 40 mL).
  3. Control Group: Patients will receive standard postoperative analgesia without interfascial blocks. This includes ketoprofen 100 mg IM at 4 hours, and oral paracetamol + ketoprofen at 12 hours. Rescue analgesia (trimeperidine 20 mg IM) will be provided if the pain score exceeds 4 on the Numerical Rating Scale (NRS).

All patients will undergo spinal anesthesia with hyperbaric bupivacaine 0.5% (2.2 mL) at the L2-L3 interspace. Preoperatively, pain threshold will be assessed using Nevidimova's method.

Outcome Measures:

The primary outcome is the intensity of visceral pain measured by the Numerical Rating Scale (NRS, 0-10) at 2, 4, 8, 12, and 16 hours postoperatively. Visceral pain is defined as dull, cramping lower abdominal pain.

Secondary outcomes include:

  • Intensity of somatic pain (NRS 0-10) at the same time points.
  • Time to independent mobilization (hours).
  • Time to first mother-infant skin-to-skin contact (hours).
  • Consumption of rescue analgesia (number of trimeperidine injections).
  • Incidence of adverse events (hypotension, nausea, vomiting, pruritus, signs of local anesthetic systemic toxicity).

Statistical Analysis:

Based on a power analysis (80% power, α=0.05), a minimum of 54 patients per group (162 total) is required to detect a clinically significant difference of 1.5 points in visceral pain scores. Data will be analyzed using the Kruskal-Wallis test for between-group comparisons and the Friedman test for within-group dynamics. A p-value \< 0.05 will be considered statistically significant.

Ethical Considerations:

The study is conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All participants will provide written informed consent. Personal data will be coded and stored securely. The study has been approved by the Local Ethics Committee of I.M. Sechenov First Moscow State Medical University.

03

Conditions studied

  • Postoperative Pain After Cesarean Section

Keywords

  • Cesarean section
  • postoperative pain
  • TAP block
  • ESP block
  • erector spinae plane block
  • transversus abdominis plane block
  • regional anesthesia
  • visceral pain
  • somatic pain
  • ropivacaine
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18 to 40 years.
  2. I-II.
  3. Scheduled for elective cesarean delivery under spinal anesthesia at term (37-41 weeks of gestation).
  4. Single fetus pregnancy.
  5. Provided written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Emergency cesarean delivery.
  2. to regional anesthesia (e.g., coagulation disorders, infection at the injection site, patient refusal).
  3. Known allergy to local anesthetics (ropivacaine, bupivacaine) or NSAIDs (ketoprofen).
  4. Chronic pain syndrome or regular use of opioid analgesics prior to surgery.
  5. > 35 kg/m².
  6. Multiple pregnancy (twins, triplets, etc.).
  7. Pre-eclampsia or eclampsia.
  8. Inability to communicate or understand the pain assessment scales (NRS).
  9. Previous abdominal surgery with extensive adhesions that may alter anatomy for nerve blocks.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Experimental: ESP Block Group

    Participants receive baseline multimodal analgesia (ketoprofen + paracetamol) PLUS bilateral ultrasound-guided ESP block at L1 level (20 mL of 0.375% ropivacaine per side). No trimeperidine is administered in this group.

    Drug: Ropivacaine · Procedure: Ultrasound-guided Nerve Block · Drug: Ketoprofen and Paracetamol · Procedure: Ultrasound-guided ESP Block

  • Experimental
    Experimental: TAP Block Group

    Participants receive baseline multimodal analgesia (ketoprofen + paracetamol) PLUS bilateral ultrasound-guided TAP block (20 mL of 0.375% ropivacaine per side). No trimeperidine is administered in this group.

    Drug: Ropivacaine · Procedure: Ultrasound-guided Nerve Block · Drug: Ketoprofen and Paracetamol · Procedure: Ultrasound-guided TAP Block

  • Active comparator
    Active Comparator: Standard Analgesia Group

    Participants receive baseline multimodal analgesia (ketoprofen + paracetamol) WITHOUT interfascial blocks. Rescue analgesia with trimeperidine 20 mg IM is available if NRS \> 4.

    Drug: Ketoprofen and Paracetamol · Drug: Trimeperidine (Rescue)

Interventions

  • 0.375% solution for ultrasound-guided nerve blocks.

  • ProcedureUltrasound-guided Nerve Block

    Bilateral TAP or ESP block performed in the post-anesthesia care unit.

  • DrugKetoprofen and Paracetamol

    Drug pages: KetoprofenStudies of KetoprofenKetoprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Baseline multimodal analgesia administered to ALL groups: Ketoprofen 100 mg IM at 4 hours postoperatively, followed by oral paracetamol + ketoprofen at 12 hours.

  • DrugTrimeperidine (Rescue)

    Rescue analgesia (Trimeperidine 20 mg IM) administered ONLY in the Control Group if NRS pain score \> 4.

  • ProcedureUltrasound-guided ESP Block

    Bilateral ESP block at L1 level with 20 mL of 0.375% ropivacaine per side.

  • ProcedureUltrasound-guided TAP Block

    Bilateral TAP block with 20 mL of 0.375% ropivacaine per side.

  • 0.375% solution for nerve blocks.

06

What researchers measure

Primary outcomes

  1. Intensity of visceral pain at 16 hours postoperatively

    Visceral pain intensity will be assessed using the Numerical Rating Scale (NRS, 0-10) at 2, 4, 8, 12, and 16 hours after surgery. The primary endpoint is the NRS score at 16 hours. Visceral pain is defined as dull, cramping lower abdominal pain.

    Time frame: 2, 4, 8, 12, and 16 hours postoperatively

Secondary outcomes

  1. Intensity of somatic pain at 16 hours postoperatively

    Somatic pain intensity (incisional pain) will be assessed using the Numerical Rating Scale (NRS, 0-10) at the same time points as visceral pain.

    Time frame: 2, 4, 8, 12, and 16 hours postoperatively

  2. Time to first independent mobilization

    Time (in hours) from the end of surgery to the patient's first attempt to sit up or stand without assistance.

    Time frame: Within 24 hours postoperatively

  3. Time to first mother-infant skin-to-skin contact

    Time (in hours) from the end of surgery to the first sustained skin-to-skin contact between the mother and the newborn.

    Time frame: Within 24 hours postoperatively

  4. Consumption of rescue analgesia

    Number of patients requiring rescue analgesia (trimeperidine 20 mg IM) due to NRS pain score \> 4.

    Time frame: Within 24 hours postoperatively

  5. Incidence of adverse events

    Frequency of hypotension, nausea, vomiting, pruritus, and signs of local anesthetic systemic toxicity (LAST).

    Time frame: Within 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
  • Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog
    Taganrog, Rostov Oblast 347900, Russia
    Recruiting
    • Aleksandr A. Bezverkhiy, PhD · Contactaab@arekusand.ru · +79034300922
    • Aleksandr A. Bezverkhiy, PhD · Principal investigator
    • Larisa V. Smekalkina, Professor · Sub investigator
    • Nikolay N. Chernov, Professor · Sub investigator
    • Daria V. Glotova, MD · Sub investigator
    • Sergey V. Zdiruk, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to strict national regulations on the protection of personal health information in the Russian Federation and to ensure the complete confidentiality and privacy of study participants. Data will be available only to the principal investigator and the local ethics committee for verification purposes.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for May 2027, 6 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 6 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 1, 2026
StartActual
Oct 16, 2026
Primary completionEst.
May 10, 2027
CompletionEst.
Jun 10, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog is now Recruiting
Nov 18, 2026
Start date
Oct 15, 2026→Oct 16, 2026 (actual)
Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog · Taganrog, RussiaContact person changed (no phone or email listed)
Oct 6, 2026
Title
TAP vs. ESP Blocks for Post-Cesarean Analgesia: A Randomized Controlled Trial
Oct 6, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 3 updates
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog is now Recruiting
    Start date Oct 15, 2026→Oct 16, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 6, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog · Taganrog, RussiaContact person changed (no phone or email listed)
    Title TAP vs. ESP Blocks for Post-Cesarean Analgesia: A Randomized Controlled Trial
    + 1 other change: verification date
  3. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853482
Lead sponsor
Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog
Responsible party
Alexander Bezverkhiy (Head of Department of Anaesthesiology and Intensive Care; Associate Professor, Southern Federal University (Advanced Engineering School); PhD in Engineering, Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog) — Principal investigator
First posted
Oct 1, 2026
Start date
Oct 16, 2026
Primary completion
May 10, 2027 (estimated)
Completion
Jun 10, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Aleksandr A. Bezverkhiy, PhD
Contact
aab@arekusand.ru
+79034300922
Aleksandr A. Bezverkhiy, PhD
principal investigator · Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion